UNSPSC 51293005: Butriptyline

This classification denotes an antidepressant agent with the molecular formula C21H27N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z22441975X, chemically known as 10,11-dihydro-n,n,beta-trimethyl-5h-dibenzo(a,d)cycloheptene-5-propylamine but generally known as butriptyline, which bears US NIH Compound Identifier 21772. Butriptyline most often comes in base, butriptylene, and hydrochloride forms.

UNSPSC 51293005 Butriptyline is a Commodity code for a specific pharmaceutical product, yet state and local procurement activity under this code shows minimal relevant recent posting. The single opportunity in the recent record—Seminole County, Florida's IFB 60459723LAS—solicits Naloxone and Safe Drug Deactivation Systems, which is unrelated to the code's nominal pharmaceutical scope. This mismatch suggests that the code does not capture material state and local procurement volume for Butriptyline or closely related products, or that issuing bodies are tagging opportunities with codes that diverge from actual line-item content.

Seminole County's naloxone and drug deactivation procurement, posted June 30, 2026, with a response deadline of July 26, 2023 (bearing an internally inconsistent date span), sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive sealed bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors had to submit bids electronically, include all shipping and delivery costs in pricing, hold drug-free workplace certification and E-Verify compliance, and maintain specified insurance coverages. The contract carried an initial two-year term with one-year renewal option and included a three-month probationary termination clause. No explicit set-asides for disadvantaged enterprises were stated, and potential FEMA funding introduced additional federal compliance obligations.